115. Immune-modulation therapy in a CRIM negative Pompe disease patient blocks antibody formation towards Myozyme, reverses cardiomyopathy, and prolongs survival
William J. Rhead(Children's Hospital of Wisconsin), Priya S. Kishnani(Duke Medical Center), Cara Wells(Children's Hospital of Wisconsin), David J. Margolis(Duke University)
Cited by 1
Related Papers
Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders
|New England Journal of Medicine|2007|357
Glycogen Storage Disease Type III diagnosis and management guidelines
|Genetics in Medicine|2010|305
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
|Genetics in Medicine|2009|292
Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation
|Proceedings of the National Academy of Sciences|1998|254
‘Classical’ organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: Long‐term outcome and effects of expanded newborn screening using tandem mass spectrometry
|Journal of Inherited Metabolic Disease|2006|247